Zhang LF, Chen LX, Yang WJ, Hu B. Albumin-bilirubin score in non-malignant liver and other diseases. World J Gastroenterol 2024; 30(41): 4481-4483 [DOI: 10.3748/wjg.v30.i41.4481]
Corresponding Author of This Article
Bing Hu, MD, Professor, Department of Gastroenterology and Hepatology, West China Hospital, Sichuan University, No. 37 Guoxue Alley, Chengdu 610041, Sichuan Province, China. hubing@wchscu.edu.cn
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Li-Fan Zhang, Liu-Xiang Chen, Wen-Juan Yang, Bing Hu, Department of Gastroenterology and Hepatology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
Li-Fan Zhang, Liu-Xiang Chen, Wen-Juan Yang, Bing Hu, Digestive Endoscopy Medical Engineering Research Laboratory, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
Author contributions: Zhang LF drafted the manuscript; Chen LX, Yang WJ, and Hu B revised the manuscript; All authors read and approved the final version of the manuscript to be published.
Supported bythe Natural Science Foundation of Sichuan Province, China, No. 2022NSFSC0819.
Conflict-of-interest statement: All authors declare no conflicts of interest in publishing the manuscript.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Bing Hu, MD, Professor, Department of Gastroenterology and Hepatology, West China Hospital, Sichuan University, No. 37 Guoxue Alley, Chengdu 610041, Sichuan Province, China. hubing@wchscu.edu.cn
Received: March 27, 2024 Revised: September 17, 2024 Accepted: September 29, 2024 Published online: November 7, 2024 Processing time: 209 Days and 13.2 Hours
Abstract
The albumin-bilirubin (ALBI) score is derived from albumin and bilirubin levels. Currently, the ALBI score is widely used in various clinical settings. A recent article in the World Journal of Gastroenterology summarized the application of the ALBI score in various non-malignant liver diseases. The ALBI score has a predictive power that is superior or non-inferior to established numerous measures. This may be related to its contiguity, sensitivity, and inclusion of albumin. While we recognize the good results of the ALBI score in a number of diseases, the ALBI score also has limitations. Variation studies for population characteristics and other factors should be performed to validate the performance of ALBI. Further modifications or optimization of ALBI scores should be taken into account.
Core Tip: A recent article in the World Journal of Gastroenterology reviewed the application of the albumin-bilirubin (ALBI) score in various liver diseases. The ALBI score shows predictive power comparable to established measures, possibly due to its continuity, sensitivity, and inclusion of albumin. However, despite promising results, the ALBI score has limitations. We believe population-specific validation studies and consideration of modifying factors are essential to ensure its accuracy and reliability in diverse patient populations.
Citation: Zhang LF, Chen LX, Yang WJ, Hu B. Albumin-bilirubin score in non-malignant liver and other diseases. World J Gastroenterol 2024; 30(41): 4481-4483
The albumin-bilirubin (ALBI) score is a measure of liver function that is calculated using albumin and bilirubin levels. The formula for calculating the ALBI score is: ALBI score = 0.66 × log10 (total bilirubin in μmol) - 0.085 × (albumin in g/L)[1]. The score is stratified into three grades: (1) Grade I (≤ -2.60); (2) Grade II (> -2.60, but ≤ -1.39); and (3) Grade III (> -1.39). A high ALBI score indicates impaired liver function due to elevated bilirubin and reduced albumin levels.
ALBI SCORE
The ALBI score was first used to evaluate liver function in patients with hepatocellular carcinoma and has since been extended to assess non-malignant liver diseases[2]. In the current issue of the World Journal of Gastroenterology, Xu et al[3] reviewed the role of the ALBI score in primary biliary cholangitis, hepatitis, cirrhosis, and liver transplantation. ALBI is an outperformed prognostic factor for progression, liver failure, mortality, and liver transplantation compared to Child-Pugh, model for end-stage liver disease (MELD), Mayo risk, etc. Furthermore, previous studies have proposed its potential applications in areas such as malnutrition[4] and treatment response[5].
The ALBI score has demonstrated superiority or non-inferiority to established measures such as Child-Pugh[6] and the MELD[7] in predicting outcomes such as prognosis[8] and mortality[9]. Due to its continuous calculation, the ALBI score allows for nuanced assessment without the use of discrete cutoff values (Table 1). In addition, its continuous calculation improves its sensitivity to small changes in bilirubin and albumin levels, making it a superior model compared to discrete score, such as Child-Pugh. The inclusion of albumin, a less commonly used parameter compared to bilirubin, contributes to its superior performance. In addition, fewer included factors and objective factors such as hepatic encephalopathy also make ALBI convenient and robust.
Table 1 Comparison of Child-Pugh, model for end-stage liver disease, and albumin-bilirubin.
Parameter
Child-Pugh
Model for end-stage liver disease
Albumin-bilirubin
Included factors
Bilirubin, albumin, hepatic encephalopathy, ascites, prothrombin time
Creatinine, bilirubin, hemodialysis, international normalized ratio
Bilirubin, albumin
Calculation
Grading score, discontinuous
Formula, continuous
Formula, continuous
Application
Liver cirrhosis
End-stage liver disease
Liver disease
However, the ALBI score has limitations. Inconsistent performance across studies may result from variability in population characteristics and other factors, requiring rigorous validation through large-scale trials[10]. In addition, it does not comprehensively encompass all diseases or outcomes, requiring careful consideration and potential modifications for specific conditions. Furthermore, the ability of the ALBI score to generalize in a simple computational way presents a dilemma when combined with other factors[10]. Combinations with other factors may improve performance on specific diseases, but this may reduce its ability to generalize. In addition, some studies have reported the prognostic ability of ALBI on heart failure[11], non-small cell lung cancer[12], nervous system tumors[13], etc. A simple formula leads to greater generalization and lower specificity. Any modifications should be carefully considered and extensively validated. Furthermore, many diseases besides liver disease can cause changes in albumin and bilirubin. The potential application of ALBI on other diseases is worthy of further research.
CONCLUSION
Despite these challenges, we believe that the ALBI score has potential as an indicator and will be used in more diseases or outcomes. Further research will validate its performance and expand or clarify its indications.
Footnotes
Provenance and peer review: Invited article; Externally peer reviewed.
Peer-review model: Single blind
Specialty type: Gastroenterology and hepatology
Country of origin: China
Peer-review report’s classification
Scientific Quality: Grade C
Novelty: Grade B
Creativity or Innovation: Grade B
Scientific Significance: Grade B
P-Reviewer: Liu LJ S-Editor: Luo ML L-Editor: Filipodia P-Editor: Yu HG
Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, O'Beirne J, Fox R, Skowronska A, Palmer D, Yeo W, Mo F, Lai P, Iñarrairaegui M, Chan SL, Sangro B, Miksad R, Tada T, Kumada T, Toyoda H. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade.J Clin Oncol. 2015;33:550-558.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 1174][Cited by in F6Publishing: 1785][Article Influence: 178.5][Reference Citation Analysis (0)]
Kotoh Y, Saeki I, Yamasaki T, Sasaki R, Tanabe N, Oono T, Maeda M, Hidaka I, Ishikawa T, Takami T, Sakaida I. Albumin-bilirubin score as a useful predictor of energy malnutrition in patients with hepatocellular carcinoma.Clin Nutr. 2021;40:3585-3591.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 2][Cited by in F6Publishing: 5][Article Influence: 1.3][Reference Citation Analysis (0)]
Cheng W, Duan L, Xu J, Shu Y, Qiu H, Yin G. Prognostic value of the albumin-bilirubin score in patients with non-Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis.Front Immunol. 2023;14:1162320.
[PubMed] [DOI][Cited in This Article: ][Reference Citation Analysis (0)]
Pasta A, Calabrese F, Plaz Torres MC, Bodini G, Furnari M, Savarino EV, Savarino V, Giannini EG, Marabotto E. Albumin-bilirubin score in non-malignant liver diseases should be properly validated.World J Gastroenterol. 2023;29:6089-6091.
[PubMed] [DOI][Cited in This Article: ][Reference Citation Analysis (0)]
Kinoshita F, Yamashita T, Oku Y, Kosai K, Ono Y, Wakasu S, Haratake N, Toyokawa G, Takenaka T, Tagawa T, Shimokawa M, Nakashima N, Mori M. Prognostic Impact of Albumin-bilirubin (ALBI) Grade on Non-small Lung Cell Carcinoma: A Propensity-score Matched Analysis.Anticancer Res. 2021;41:1621-1628.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 3][Cited by in F6Publishing: 13][Article Influence: 4.3][Reference Citation Analysis (0)]